Jeffrey Whitten

TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

Alexander Drilon, Evan Rogers, Dayong Zhai et al. · Annals of Oncology · 2019 · 57 citations

Medicine, Oncology, Pharmacology +12

TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants

J. Jean Cui, Dayong Zhai, Wei Deng et al. · European Journal of Cancer · 2016 · 30 citations

Medicine, Medicinal Chemistry, Oncology +17

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

Alexander Drilon, Dayong Zhai, Wei Deng et al. · Cancer Research · 2019 · 28 citations

Medicine, Oncology, Pharmacology +17

Stereospecific syntheses of the four diastereomeric 2-amino-5-phenoxycyclopentanols

James R. McCarthy, Paul E. Wiedeman, Albert J. Schuster et al. · The Journal of Organic Chemistry · 1985 · 17 citations

Natural Sciences, Chemistry, Medicinal Chemistry +6

CM3457, a potent and selective oral CRAC channel inhibitor, suppresses T and mast cell function and is efficacious in rat models of arthritis and asthma (72.3)

Stephanie Ramos, Sergey Grigoryev, E. W. Rogers et al. · The Journal of Immunology · 2012 · 11 citations

Life Sciences, Pharmacology, Pharmacotherapy +17